![Paul Schneider](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Paul M.
Schneider is currently the Chief Financial Officer at Freeline Therapeutics Holdings Plc.
Prior to his current position, he served as the Senior Vice President-Finance at Casebia Therapeutics LLC from 2016 to 2019.
He also held the position of Senior Vice President-Finance & Operations at Exo Therapeutics, Inc. Mr. Schneider completed his undergraduate degree at Boston College.
Tidigare kända positioner av Paul Schneider
| Företag | Position | Slut |
|---|---|---|
Casebia Therapeutics LLC
 Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Discovers, develops and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders, autoimmune disease | Företagsledare/Principal | 2019-09-01 |
Exo Therapeutics, Inc.
 Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs and small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes | Finansdirektör/CFO | - |
| FREELINE THERAPEUTICS HOLDINGS PLC | Finansdirektör/CFO | - |
Paul Schneiders utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
4
Första gradens relationer
4
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
Boston College
 Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Casebia Therapeutics LLC
Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Discovers, develops and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders, autoimmune disease | Health Technology |
Exo Therapeutics, Inc.
Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs and small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes | Health Technology |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Develops and manufactures next-generation gene therapies | Health Technology |
